Literature DB >> 32730784

Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?

Adam Palayew1, Homie Razavi2, Sharon J Hutchinson3, Graham S Cooke4, Jeffrey V Lazarus5.   

Abstract

In 2019, a Lancet Gastroenterology & Hepatology Commission on accelerating the elimination of viral hepatitis reported on the status of 11 viral hepatitis policy indicators in 66 countries and territories with the heaviest burden by global region. Policies were reported as being either in place, in development, or not in place. This study uses the Commission findings to estimate hepatitis B virus (HBV) and hepatitis C virus (HCV) policy scores and rankings for these 66 countries and territories. We applied a multiple correspondence analysis technique to reduce data on policy indicators into a weighted summary for the HBV and HCV policies. We calculated HBV and HCV policy scores for each country. Countries and territories that received higher scores had more policies in place and in development than did countries with lower scores. The highest scoring country for HBV was Australia, whereas Somalia had the lowest score. For the HCV policy score, Australia and New Zealand had perfect scores, whereas Somalia, Sudan, and Yemen had the lowest scores, all having no policy indicators in place.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32730784     DOI: 10.1016/S2468-1253(20)30011-X

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  4 in total

1.  Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis.

Authors:  Barnaby Flower; Duc Du Hong; Hang Vu Thi Kim; Khue Pham Minh; Ronald B Geskus; Jeremy Day; Graham S Cooke
Journal:  Lancet Reg Health West Pac       Date:  2022-05-04

2.  Elimination of hepatitis C: What would be the practical approach?

Authors:  Hyung Joon Yim
Journal:  Clin Mol Hepatol       Date:  2020-12-03

3.  European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?

Authors:  Jeffrey V Lazarus; Adam Palayew; Patrizia Carrieri; Mattias Ekstedt; Giulio Marchesini; Katja Novak; Vlad Ratziu; Manuel Romero-Gómez; Frank Tacke; Shira Zelber-Sagi; Helena Cortez-Pinto; Quentin M Anstee
Journal:  JHEP Rep       Date:  2021-01-21

4.  Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.

Authors:  Yvonne A Nartey; Samuel O Antwi; Ansumana S Bockarie; Lindsey Hiebert; Henry Njuguna; John W Ward; Yaw A Awuku; Amelie Plymoth; Lewis R Roberts
Journal:  PLoS One       Date:  2022-09-13       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.